Global Breast Cancer Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 - 2025

  • ID: 4394887
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • AstraZeneca plc
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis International AG
  • MORE
Breast Cancer Treatment Market - Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2017 - 2025, the breast cancer treatment market was valued at USD 12,306.3 Mn in 2017, and is expected to reach USD 18,801.3 Mn by 2025, expanding at a CAGR of 7.6% from 2017 - 2025.

Market Insights

Breast cancer is typically detected either during a screening examination, before symptoms have developed, or after a woman notices a lump. According to market experts, breast cancer is the second-largest cause of cancer deaths globally. The rising prevalence of breast cancer across the developed nations has boosted the involvement of non-governmental associations that are spreading awareness related to breast cancer diagnostics and treatment in public. Therapeutic treatment preferred to treat breast cancer involves synthetic to biological drugs. The awareness created around the world in last decade has assisted the market growth along with market introduction of premium priced therapies. Moreover, drugs for breast cancer have seen accelerated approvals, thereby providing impetus for breast cancer research and shifting the equilibrium toward research of new effective pathways for intervention of breast cancer. On the other hand, the geographical analysis of breast cancer treatment market projected North America and Europe as the dominant regions followed by Asia-Pacific. The key factors driving the breast cancer market in the world include developed research and development facilities, upcoming drug launches, and mounting incidences and awareness of the breast cancer in developing countries. Thus, rising incidences of breast cancer and novel product approvals will lead to significant market growth during the forecast period, despite generic sales erosion resulting from patent expirations.

Pipeline Analysis:

The phase III drugs included in the pipeline analysis are Abemaciclib (Eli Lily & Company), Buparlisib (Novartis), NeuVax (Galena Biopharma), Niraparib (Tesaro), Lynparza (AstraZeneca), Veliparib (AbbVie), Neratinib (Puma Biotechnology), Ribociclib (Novartis) and others. According to market experts, these upcoming drugs assure to provide enhanced efficacy, shorter onset of action and fewer side effects as compared to the currently available breast cancer treatment. Thus, future commercialization of these molecules during the forecast period 2016 - 2022 is anticipated to have a reflective impact on the growth of the overall breast cancer treatment market.

Key Market Movements:
  • North America presently dominates the overall market and is also projected to experience the fastest growth throughout the forecast period
  • The recent market entry of novel drugs including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent have boosted the overall growth of breast cancer treatment market
  • The companies have been able to develop efficient and commercially successful products by studying pathophysiology of breast cancer in detail, e.g. Herceptin, which is build on the existing scientific groundwork.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca plc
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis International AG
  • MORE
Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Breast Cancer Treatment Market Portaiture
2.2 Global Breast Cancer Treatment Market Treament Market, by Drug Class, 2015 (USD Mn)
2.3 Relativity Analysis: Global Breast Cancer Treatment Market, by Geography, 2015 & 2022 (USD Mn)

Chapter 3 Breast Cancer Treatment : Market Dynamics and Outlook
3.1 Breast Cancer Treatment Market Overview
3.2 Breast Cancer Disease Overview and Treatments
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Breast Cancer Treatment Market, 2015 (Value %)

Chapter 4 Global Breast Cancer Treatment Market, By Type of Drug Class
4.1 Preface
4.2 HER2 Inhibitors
4.2.1 Trastuzumab
4.2.2 Pertuzumab
4.2.3 Ado-trastuzumab emtansine
4.2.4 Lapatinib
4.3 Mitotic Inhibitors
4.3.1 Eribulin
4.3.2 Docetaxel
4.3.3 Ixabepilone
4.4 Anti-metabolites
4.4.1 Gemcitabine
4.5 Aromatase Inhibitors
4.5.1 Leterozole
4.5.2 Exemestane
4.5.3 Anastrozole
4.5.4 Palbociclib
4.5.5 Everolimus
4.6 Hormone Receptor Antagonists
4.6.1 Goserelin Acetate
4.6.2 Fulvestrant
4.6.3 Toremifene
4.7 Pipeline Analysis
4.7.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.7.1.1 Abemaciclib
4.7.1.2 Buparlisib
4.7.1.3 NeuVax
4.7.1.4 Niraparib
4.7.1.5 Lynparza
4.7.1.6 Veliparib
4.7.1.7 Neratinib
4.7.1.8 Ribociclib
4.7.1.9 Others
4.7.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Breast Cancer Treatment Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia-Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Latin America
5.4.1 Brazil
5.4.2 Mexico
5.4.3 Rest of Latin America
5.6 Middle East and Africa

Chapter 6 Company Profiles
6.1 AstraZeneca plc
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
7.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Eisai Co., Ltd.
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Eli Lilly and Company
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
6.3.4 News Coverage
6.4 F. Hoffmann-La Roche Ltd.
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Portfolio
6.4.4 News Coverage
6.5 GlaxoSmithKline plc
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Portfolio
6.5.4 News Coverage
6.6 Novartis International AG
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product portfolio
6.6.4 News Coverage
6.7 Pfizer, Inc.
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Portfolio
6.7.4 News Coverage
6.8 Puma Biotechnology, Inc.
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Portfolio
6.8.4 News Coverage
6.9 Sanofi S.A.
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Portfolio
6.9.4 News Coverage
6.10 Teva Pharmaceutical Industries Ltd.
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage

List of Figures
Fig. 1 Global Breast Cancer Treatment Market, by Type of Drug Class, 2015 (USD Mn)
Fig. 2 Relativity Analysis: Global Breast Cancer Treatment Market, by Geography, 2015 & 2025 (USD Mn)
Fig. 3 Attractive Investment Proposition, Global Breast Cancer Treatment Market, 2015
Fig. 4 Market Share Analysis: Global Breast Cancer Treatment Market, 2015 (Value %)
Fig. 5 Global Trastuzumab Market, 2015 - 2025 (USD Mn)
Fig. 6 Global Pertuzumab Market, 2015- 2025 (USD Mn)
Fig. 7 Global Ado-trastuzumab Emtansine Market, 2015 -2025 (USD Mn)
Fig. 8 Global Lapatinib Market, 2015 - 2025 (USD Mn)
Fig. 9 Global Eribulin Market, 2015- 2025 (USD Mn)
Fig. 10 Global Docetaxel Market, 2015 -2025 (USD Mn)
Fig. 11 Global Ixabepilone Market, 2015 - 2025 (USD Mn)
Fig. 12 Global Gemcitabine Market, 2015- 2025 (USD Mn)
Fig. 13 Global Leterozole Market, 2015 -2025 (USD Mn)
Fig. 14 Global Exemestane Market, 2015 -2025 (USD Mn)
Fig. 15 Global Anastrozole Market, 2015 -2025 (USD Mn)
Fig. 16 Global Palbociclib Market, 2015 -2025 (USD Mn)
Fig. 17 Global Everolimus Market, 2015 -2025 (USD Mn)
Fig. 18 Pipeline Analysis: Global Abemaciclib Market, Upto 2025 (USD Mn)
Fig. 19 Pipeline Analysis: Global Buparlisib Market, Upto 2025 (USD Mn)
Fig. 20 Pipeline Analysis: Global NeuVax Market, Upto 2025 (USD Mn)
Fig. 21 Pipeline Analysis: Global Niraparib Market , Upto 2025 (USD Mn)
Fig. 22 Pipeline Analysis: Global Lynparza Market, Upto 2025 (USD Mn)
Fig. 23 Pipeline Analysis: Global Veliparib Market, Upto 2025 (USD Mn)
Fig. 24 Pipeline Analysis: Global Neratinib Market, Upto 2025 (USD Mn)
Fig. 25 Pipeline Analysis: Global Ribociclib Market, Upto 2025 (USD Mn)
Fig. 26 Global U.S.Breast Cancer Treatment Market, 2015 - 2025 (USD Mn)
Fig. 27 Global Canada Breast Cancer Treatment Market, 2015 - 2025 (USD Mn)
Fig. 28 Global U.K Breast Cancer Treatment Market, 2015 - 2025 (USD Mn)
Fig. 29 Global Germany Breast Cancer Treatment Market, 2015 - 2025 (USD Mn)
Fig. 30 Global Rest of Europe Breast Cancer Treatment Market, 2015 - 2025 (USD Mn)
Fig. 31 Global China Breast Cancer Treatment Market, 2015 - 2025 (USD Mn)
Fig. 32 Global Japan Breast Cancer Treatment Market, 2015 - 2025 (USD Mn)
Fig. 33 Global Rest of Asia Pacific Breast Cancer Treatment Market, 2015 - 2025 (USD Mn)
Fig. 34 Global Brazil Breast Cancer Treatment Market, 2015 - 2025 (USD Mn)
Fig. 35 Global Mexico Breast Cancer Treatment Market, 2015 - 2025 (USD Mn)
Fig. 36 Global Rest of the Latin America Breast Cancer Treatment Market, 2015 - 2025 (USD Mn)
Fig. 37 Global Middle East and Africa Breast Cancer Treatment Market, 2015 - 2025 (USD Mn)

List of Tables
Table 1 Global Breast Cancer Treatment Market, by Type of Drug Class, 2015 - 2025 (USD Mn)
Table 2 Global Breast Cancer Treatment Market, by Geography, 2015 - 2025 (USD Mn)
Table 3 Global HER 2 Inhibitors Market, 2015 - 2025 (USD Mn)
Table 4 Global Mitotic Inhibitors Market, 2015 - 2025 (USD Mn)
Table 5 Global Aromatase Inhibitors Market, 2015 - 2025 (USD Mn)
Table 6 Global Hormone Receptor Antagonists Market, 2015 - 2025 (USD Mn)
Table 7 North America Breast Cancer Treatment Market, by Country, 2015 - 2025 (USD Mn)
Table 8 Europe Breast Cancer Treatment Market, by Country, 2015 - 2025 (USD Mn)
Table 9 Asia - Pacific Breast Cancer Treatment Market, by Country, 2015 - 2025 (USD Mn)
Table 10 Latin America Breast Cancer Treatment Market, by Country, 2015 - 2025 (USD Mn)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AstraZeneca plc
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis International AG
  • Pfizer, Inc.
  • Puma Biotechnology, Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll